Diabetes Tele-Management System (DTMS®), a telemedicine (TM)-based intervention and follow-up program for diabetes management comprising of a multidisciplinary team performs drug titration, provides dietary advice & educates the patients and their caregivers periodically with the help of customized software and user interface. The study was done to examine the long-term effect of TM consultation along with face-to-face consultation (F-F) in metabolic control & prevention of complications. A total of 495 T2D (62.91 ± 11.64 years (Y); 62.2% males, duration of diabetes: 8.41 ± 2.78 Y), were de-identified. The treatment group [TG- 63.41±11.73 Y; 62.92% males; 8.04±1.82 Y of T2D] included T2D with ≥1F-F and ≥5 TM consultations per year. The propensity score-matched control group [CG-62.17±11.50 Y; 58.69% males; 7.98±2.96 Y of T2D] included T2D who were not on regular follow-up with compromised F-F and TM visits. Data of 15±5 years were collected from DTMS and statistically analyzed. Significant improvement (p < 0.001) in clinical parameters including HbA1c, FBS, lipid profile, BP & weight from baseline to 10 Y of follow up was observed in TG. 9.8% in TG and 82.1% in CG had diabetic complications (Table 1). This 15 year long real-world experience reveals a robust difference between the 2 arms providing compelling evidence to fund TM consultations.


J.Kesavadev: None. A.Shankar: None. K.Jothydev: None. S.R.Joshi: Advisory Panel; Biocon, Zydus Cadila, Torrent Pharmaceuticals Ltd, Franco India, Consultant; Glenmark Pharmaceuticals, Twin Health, Speaker's Bureau; Abbott Nutrition, Sanofi, Abbott, Novo Nordisk, Lupin Pharmaceuticals, Inc. G.Krishnan: None. G.Sanal: None. A.Basanth: None. G.B.Chandran: None. S.Jothydev: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.